Internal Medicine, Hematology & Oncology · Philadelphia, PA
NPI
1124000278
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
5501 Old York Road, Albert Einstein Medical Center
Philadelphia, PA, 19141
Phone (215) 456-3800
Groups this clinician bills Medicare through
Medicare paid, 2024
$90K
961 services
Medicare patients, 2024
409
Average age 76
Drug cost, 2024
$4.1M
1,291 prescriptions
Company payments, 2025
$441
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark S Morginstin was code 99214 (office e&m - established), 503 times for 282 patients. In total Mark S Morginstin billed 961 services in 10 codes, and Medicare paid $90K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-06-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 503 | 282 | $75.96 | $38K |
| 99215 Office E&M - Established | Facility | 265 | 103 | $112.16 | $30K |
| 99222 Hospital E&M - Initial | Facility | 75 | 72 | $103.58 | $7,769 |
| 99233 Hospital E&M - Subsequent | Facility | 57 | 37 | $97.83 | $5,577 |
| 99205 Office E&M - New | Facility | 52 | 52 | $147.04 | $7,646 |
By year: 2022 $75K for 800 services; 2023 $78K for 892 services; 2024 $90K for 961 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mark S Morginstin prescribed most often to Medicare patients was Anastrozole, with 211 prescriptions and refills. In total Mark S Morginstin wrote 1,291 Medicare prescriptions that cost $4.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 211 | 419 | 49 | $4,432 |
| Eliquis Apixaban | 167 | 236 | 34 | $135K |
| Hydroxyurea Generic | 90 | 198 | 20 | $3,065 |
| Warfarin Sodium Generic | 81 | 103 | Under 11 | $419 |
| Letrozole Generic | 67 | 176 | 21 | $1,609 |
| Revlimid Lenalidomide | 56 | 56 | Under 11 | $870K |
| Exemestane Generic | 49 | 95 | 13 | $6,520 |
| Acyclovir Generic | 34 | 52 | Under 11 | $695 |
| Ibrance Palbociclib | 28 | 28 | Under 11 | $457K |
| Ondansetron Hcl Generic | 25 | 25 | 22 | $273 |
| Brukinsa Zanubrutinib | 25 | 25 | Under 11 | $290K |
| Imbruvica Ibrutinib | 24 | 24 | Under 11 | $405K |
| Prednisone Generic | 24 | 30 | Under 11 | $70.23 |
| Methylprednisolone Generic | 22 | 22 | Under 11 | $113 |
| Gabapentin Generic | 20 | 22 | Under 11 | $175 |
Brand drugs: 449 claims; generic drugs: 842 claims; opioid claims: 37.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark S Morginstin $441 ($441 in general payments such as food, travel and fees) from 8 companies. The largest payer was Sobi, Inc with $171.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.